Last reviewed · How we verify

Furazolidone Tablets

The Third Xiangya Hospital of Central South University · FDA-approved active Small molecule Quality 5/100

Furazolidone Tablets is a Small molecule drug developed by The Third Xiangya Hospital of Central South University. It is currently FDA-approved.

At a glance

Generic nameFurazolidone Tablets
SponsorThe Third Xiangya Hospital of Central South University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Furazolidone Tablets

What is Furazolidone Tablets?

Furazolidone Tablets is a Small molecule drug developed by The Third Xiangya Hospital of Central South University.

Who makes Furazolidone Tablets?

Furazolidone Tablets is developed and marketed by The Third Xiangya Hospital of Central South University (see full The Third Xiangya Hospital of Central South University pipeline at /company/the-third-xiangya-hospital-of-central-south-university).

What development phase is Furazolidone Tablets in?

Furazolidone Tablets is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing